C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.

Troppan, KT; Schlick, K; Deutsch, A; Melchardt, T; Egle, A; Stojakovic, T; Beham-Schmid, C; Weiss, L; Neureiter, D; Wenzl, K; Greil, R; Neumeister, P; Pichler, M; Br J Cancer. 2014; 111(1):55-60

Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.

Tassara, M; Döhner, K; Brossart, P; Held, G; Götze, K; Horst, HA; Ringhoffer, M; Köhne, CH; Kremers, S; Raghavachar, A; Wulf, G; Kirchen, H; Nachbaur, D; Derigs, HG; Wattad, M; Koller, E; Brugger, W; Matzdorff, A; Greil, R; Heil, G; Paschka, P; Gaidzik, VI; Göttlicher, M; Döhner, H; Schlenk, RF; Blood. 2014; 123(26): 4027-4036.

Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.

Goede, V; Cramer, P; Busch, R; Bergmann, M; Stauch, M; Hopfinger, G; Stilgenbauer, S; Doehner, H; Westermann, A; Wendtner, CM; Eichhorst, B; Hallek, M; Haematologica. 2014; 99(6): 1095-1100.

How does lenalidomide target the chronic lymphocytic leukemia microenvironment?

Kater, AP; Tonino, SH; Egle, A; Ramsay, AG; Blood. 2014; 124(14):2184-2189

Old and new news in CLL: „It“s the pathway, stupid!“.

Egle, A; Blood. 2014; 124(7):989-990

Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives

Hohla, F; Winder, T; Greil, R; Rick, FG; Block, NL; Schally, AV WORLD J GASTROENTERO. 2014; 20(20): 6102-6112.

Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.

Hohla, F; Hopfinger, G; Romeder, F; Rinnerthaler, G; Bezan, A; Stättner, S; Hauser-Kronberger, C; Ulmer, H; Greil, R; Int J Oncol. 2014; 44(1):319-326

Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.

Gampenrieder, SP; Romeder, F; Muß, C; Pircher, M; Ressler, S; Rinnerthaler, G; Bartsch, R; Sattlberger, C; Mlineritsch, B; Greil, R; Anticancer Res. 2014; 34(1): 227-233.

Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.

Hopfinger, G; Nösslinger, T; Lang, A; Linkesch, W; Melchardt, T; Weiss, L; Egle, A; Greil, R; Ann Hematol. 2014; 93(3):459-462

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).

Hutterer, M; Nowosielski, M; Haybaeck, J; Embacher, S; Stockhammer, F; Gotwald, T; Holzner, B; Capper, D; Preusser, M; Marosi, C; Oberndorfer, S; Moik, M; Buchroithner, J; Seiz, M; Tuettenberg, J; Herrlinger, U; Wick, A; Vajkoczy, P; Stockhammer, G; Neuro Oncol. 2014; 16(1):9-102